Skip to content

Clinical research of oxymatrine on psoriasis

Clinical research of oxymatrine on psoriasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004301
Enrollment
Unknown
Registered
2014-02-15
Start date
2012-12-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Ammonia peptide hormones:Ammonia peptide hormones
Treatment Group:Oxymatrine
Contrast Group:Acitretin Capsules
Compound glycyrrhizin glucoside Group:Compound glycyrrhizin glucoside
Oxymatrine + compound glycyrrhizin glucoside:Oxymatrine + compound glycyrrhizin glucoside
Oxymatrine + compound glycyrrhizin glucoside:Oxymatrine + compound glycyrrhizin glucoside + black light
Black light:Black light
compound glycyrrhizin glucoside + black light:compound glycyrrhizin glucoside + black light

Sponsors

General Hospisal of Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 56 Years

Inclusion criteria

Inclusion criteria: Psoriasis patients, received systemic treatment at least once previously.

Exclusion criteria

Exclusion criteria: Patients who are allergic to oxymatrine, patients who are suffering from sever liver and kidney damage, mental illness, hematopoietic dysfunction and other serious organic disease, received immunosuppressor, high doses of glucocorticoid or retinoid in the past 4 weeks, pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Psoriasis area and severity index;Skin classification;Whole blood viscosity;T-AOC;MDA;SOD;GSH-Px;Immune globulin+ Complement;TNF-alpha;ICAM-1;IL-8;IL-10;Terminal deoxynucleotidyl transferase-mediated dUT;VEGF;MMP;ESAF;MCP-1;

Secondary

MeasureTime frame
Dermatology life quality index;Pathological changes of skin;Routine blood tests;Routine biochemical examinations;Routine urine tests;Mitotic figure;PCNA;tumor suppressor gene-p53;The proliferation of tumor antigen-ki6;

Countries

China

Contacts

Public ContactHuijuan Shi

General Hospisal of Ningxia Medical University

shjyjm@163.com+86 13995295912

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026